NCT06494878View on ClinicalTrials.gov

The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

8,805

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

August 31, 2030

Study Completion Date

December 31, 2030

Conditions
Venous ThromboembolismPostpartum PeriodAspirinLow Molecular Weight Heparin
Interventions
DRUG

Aspirin

75-100 mg taken once daily by mouth.

DRUG

Low-molecular-weight heparin

Low-molecular-weight heparin injections daily as prescribed by the treating physician.

Trial Locations (3)

T2N 2T9

Foothills Medical Centre, Calgary

K1H 8L6

The Ottawa Hospital - General Campus, Ottawa

M5G 1Z5

Mount Sinai Hospital, Toronto

All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

lead

University of Calgary

OTHER